Tag: SYK

SRX3207 is an Orally Active and First-in-Class Dual Syk/PI3K Inhibitor

Macrophages (MΦ) not only play a role in host defense and tumor growth, metastasis, and immunosuppression. Many studies have demonstrated that targeting the molecular pathways/signaling nodes in the MΦs that regulate the transition of protumorigenic MΦs into anti-tumorigenic MΦs will activate the immune response in cancer. Syk kinase has...

BAY 61-3606, a Syk Inhibitor, Sensitizes TRAIL-Induced Apoptosis by Downregulating Mcl-1 in Breast Cancer

Breast cancer cells usually develop resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). TRAIL shows cancer-selective killing activity. TRAIL ligand selectively kills cancer cells by initiating apoptotic signaling through the engagement of its pro-apoptotic receptors, death receptors-4 and -5. In particular, myeloid cell leukemia sequence-1 (Mcl-1) is a member...

TAK-659 is a Dual SYK and FLT-3 Kinase Inhibitor for Leukemia Treatment

Acute Myelogenous Leukemia (AML) is a disease driven by SYK and/or FLT3-mediated signaling. In particular, spleen tyrosine kinase (SYK) is a 72 kD non-receptor cytoplasmic tyrosine kinase. SYK is a key mediator for a variety of inflammatory cells and immunology signaling pathways, including B cell receptor in B cells,...